Dysplasia is considered low-grade or high-grade, depending on the degree of cellular change. "While the benefit is clear for ...

Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering nanotechnology-based cancer therapies, is ...

This arm targets patients with carcinoma in situ (CIS) and high-grade dysplasia of the oral cavity, aiming to improve local control and potentially reduce the extent of surgical intervention.